6734.TWO iXensor Co., Ltd.
- Market cap
- TWD 221M
- P/E
- -
- P/B
- 25.06x
- ROE
- -203.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6734.TWO undervalued?
Graham numberThe Graham number of iXensor Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
iXensor Co., Ltd. fundamental analysis
No fundamental analysis for iXensor Co., Ltd. yet.
iXensor Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About iXensor Co., Ltd.
iXensor Co., Ltd. engages in the research, development, and manufacture of medical devices. It offers PixoTest Vision Analysis System and PixoHealth Vision application for chronic disease monitoring, as well as Eveline Smart Fertility System and Eveline Care Telehealth Platform for women's health management. The company was founded in 2012 and is based in Taipei, Taiwan.
Full company profileiXensor Co., Ltd. financial statements
iXensor Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 30.0M | 15.9M | 24.8M | 105M | 20.9M | 19.5M | 26.9M |
| Gross Profit | 9.03M | 4.50M | 4.62M | 62.6M | 1.60M | 6.00M | 16.9M |
| Operating Income | -109M | -80.0M | -81.5M | -5.23M | -63.0M | -46.1M | -45.7M |
| EBITDA | -96.7M | -65.6M | -64.3M | 2.39M | -56.8M | -39.3M | -39.6M |
| Net Income | -105M | -76.6M | -73.1M | -4.89M | -63.2M | -46.8M | -47.0M |
| EPS | -2.15 | -1.55 | -1.40 | -0.09 | -1.15 | -2.05 | -1.16 |
| Balance Sheet | |||||||
| Total Assets | 179M | 97.5M | 73.6M | 105M | 96.4M | 74.6M | 69.0M |
| Total Liabilities | 25.8M | 18.4M | 16.6M | 24.0M | 63.6M | 64.6M | 45.9M |
| Shareholders' Equity | 154M | 79.1M | 57.0M | 80.7M | 32.7M | 10.1M | 23.1M |
| Cash & Short-term Investments | 96.8M | 40.7M | 15.4M | 47.8M | 49.0M | 39.0M | 38.3M |
| Total Debt | 10.7M | 6.16M | 1.67M | 16.7M | 52.5M | 58.9M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -97.0M | -57.2M | -72.0M | 8.12M | -46.2M | -40.3M | -36.9M |
| Capital Expenditure | 1.54M | 1.85M | 1.58M | 745K | 1.75M | 1.07M | 378K |
| Free Cash Flow | -98.5M | -59.0M | -73.5M | 7.37M | -47.9M | -40.9M | -37.3M |
| Ratios | |||||||
| ROE | -68.2% | -96.9% | -128.2% | -6.1% | -193.1% | -465.7% | -203.4% |
| ROA | -58.4% | -78.6% | -99.3% | -4.7% | -65.6% | -62.7% | -68.1% |
| Net Profit Margin | -348.5% | -481.1% | -294.7% | -4.6% | -302.5% | -240.5% | -174.7% |
| Debt to Equity | 0.07x | 0.08x | 0.03x | 0.21x | 1.60x | 5.86x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
iXensor Co., Ltd. dividends
iXensor Co., Ltd. has not paid dividends in the last 7 fiscal years.
Last stock split: 400:1000 on Aug 22, 2024.
Who owns iXensor Co., Ltd.
Ownership data of iXensor Co., Ltd. is not available yet.
iXensor Co., Ltd. company profile
- Company name
- iXensor Co., Ltd.
- Ticker
- 6734.TWO
- ISIN
- TW0006734007
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Fiscal year end
- December
- Address
- No. 9, Alley 2, Lane 35, Taipei, Taiwan, 11492
- Phone
- 886 2 8751 1335
- Website
- ixensor.com
About iXensor Co., Ltd.
iXensor Co., Ltd. engages in the research, development, and manufacture of medical devices. It offers PixoTest Vision Analysis System and PixoHealth Vision application for chronic disease monitoring, as well as Eveline Smart Fertility System and Eveline Care Telehealth Platform for women's health management. The company was founded in 2012 and is based in Taipei, Taiwan.
iXensor Co., Ltd. management
5- Dr. Yanyu Chen Ph.D.Co-Founder, Chairman, Manager & CEO
- Dr. Peter J. Fitzgerald FACC, M.D., Ph.D.Chief Advisor & Board Member · born 1957
- Dr. Alan Tsai Ph.D.Co-Founder & Project Advisor
- Dr. Jerry Chen M.D., Ph.D.Co-Founder & Medical Advisor
- Shulan HuangAccounting Supervisor